CN114568616A - Solid beverage with blood garbage cleaning effect and preparation method thereof - Google Patents
Solid beverage with blood garbage cleaning effect and preparation method thereof Download PDFInfo
- Publication number
- CN114568616A CN114568616A CN202210347772.7A CN202210347772A CN114568616A CN 114568616 A CN114568616 A CN 114568616A CN 202210347772 A CN202210347772 A CN 202210347772A CN 114568616 A CN114568616 A CN 114568616A
- Authority
- CN
- China
- Prior art keywords
- parts
- solid beverage
- blood
- green tea
- inulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007787 solid Substances 0.000 title claims abstract description 52
- 235000013361 beverage Nutrition 0.000 title claims abstract description 49
- 210000004369 blood Anatomy 0.000 title claims abstract description 47
- 239000008280 blood Substances 0.000 title claims abstract description 47
- 230000000694 effects Effects 0.000 title claims abstract description 24
- 238000004140 cleaning Methods 0.000 title claims abstract description 15
- 239000010813 municipal solid waste Substances 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title abstract description 10
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 241001558017 Gynura Species 0.000 claims abstract description 19
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 19
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 19
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 19
- 244000197580 Poria cocos Species 0.000 claims abstract description 16
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 16
- 239000000843 powder Substances 0.000 claims abstract description 16
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 14
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 14
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 14
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 14
- 244000247812 Amorphophallus rivieri Species 0.000 claims abstract description 13
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims abstract description 13
- 229920001202 Inulin Polymers 0.000 claims abstract description 13
- 229920002752 Konjac Polymers 0.000 claims abstract description 13
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 13
- 229940029339 inulin Drugs 0.000 claims abstract description 13
- 235000010485 konjac Nutrition 0.000 claims abstract description 13
- 239000000252 konjac Substances 0.000 claims abstract description 13
- 229940026510 theanine Drugs 0.000 claims abstract description 13
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 11
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 5
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 5
- 241000219784 Sophora Species 0.000 claims abstract description 5
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract 3
- 239000002699 waste material Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 18
- 244000269722 Thea sinensis Species 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 244000134552 Plantago ovata Species 0.000 claims description 8
- 235000003421 Plantago ovata Nutrition 0.000 claims description 8
- 229940094952 green tea extract Drugs 0.000 claims description 8
- 244000046101 Sophora japonica Species 0.000 claims description 7
- 235000010586 Sophora japonica Nutrition 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 235000009569 green tea Nutrition 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000010903 husk Substances 0.000 claims description 6
- 235000013616 tea Nutrition 0.000 claims description 6
- 235000004879 dioscorea Nutrition 0.000 claims description 4
- 238000003809 water extraction Methods 0.000 claims description 4
- 235000001188 Peltandra virginica Nutrition 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 4
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 3
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 235000013305 food Nutrition 0.000 abstract description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 23
- 241000700159 Rattus Species 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 17
- 230000006870 function Effects 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 108010007622 LDL Lipoproteins Proteins 0.000 description 9
- 102000007330 LDL Lipoproteins Human genes 0.000 description 9
- 230000002146 bilateral effect Effects 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 8
- 239000000284 extract Substances 0.000 description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 6
- 229960000672 rosuvastatin Drugs 0.000 description 6
- 102000004420 Creatine Kinase Human genes 0.000 description 5
- 108010042126 Creatine kinase Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 208000035150 Hypercholesterolemia Diseases 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000002969 egg yolk Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000009223 Psyllium Substances 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000003833 bile salt Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002504 lithotomy Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229940070687 psyllium Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 241000157855 Cinchona Species 0.000 description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000034800 Leukoencephalopathies Diseases 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241001127637 Plantago Species 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000004227 basal ganglia Anatomy 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000000518 rheometry Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010060965 Arterial stenosis Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000031856 Haemosiderosis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 235000003417 Plumeria rubra f acutifolia Nutrition 0.000 description 1
- 244000040691 Plumeria rubra f. acutifolia Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940104640 chinese yam extract Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- YUOUGYOAHCSPDY-UHFFFAOYSA-N pentaoxazinane Chemical compound N1OOOOO1 YUOUGYOAHCSPDY-UHFFFAOYSA-N 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 125000003410 quininyl group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000002385 vertebral artery Anatomy 0.000 description 1
- 239000002912 waste gas Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Non-Alcoholic Beverages (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a solid beverage with a blood garbage cleaning effect and a preparation method thereof, and relates to the technical field of health-care food. The raw materials of the solid beverage comprise a traditional Chinese medicine composition, and the traditional Chinese medicine composition comprises the following components in parts by mass: 1-20 parts of inulin, 1-20 parts of Chinese yam, 1-20 parts of poria cocos, 1-10 parts of konjac fine powder, 1-20 parts of gynura divaricata, 1-10 parts of lotus leaves, 1-10 parts of theanine, 1-10 parts of sophora flower buds, 1-10 parts of green tea extracts and 1-10 parts of plantain seed hulls. The invention provides a solid beverage with the function of clearing blood garbage, which can well clear the blood garbage after being taken for 1-2 months before eating, can prevent the blood garbage from accumulating in the blood after being taken for a long time, can prevent cardiovascular and cerebrovascular diseases and is beneficial to body health.
Description
Technical Field
The invention relates to the technical field of health-care food, in particular to a solid beverage with a function of cleaning blood waste and a preparation method thereof.
Background
When blood in the body metabolizes waste, such as: excessive accumulation of triglycerides, low density lipoproteins, free radicals, cholesterol, uric acid, urea, bilirubin, creatinine, carbon dioxide, etc., can result in increased blood viscosity, reduced blood flow rate, decreased blood vessel elasticity, and blood vessel congestion. The long-term occurrence of blood viscosity can form thrombus plaques and vascular atherosclerosis, thereby affecting the blood circulation system, causing insufficient blood supply of heart and brain, and easily causing the occurrence of cardiovascular and cerebrovascular diseases. In addition, the medicine also causes the problems of hyperlipidemia, hypertension, obesity, rheumatoid arthritis, female premature senility, skin problems, male sexual function, dampness and the like, and the main symptoms are as follows: chest pain, chest distress, insomnia, amnesia, headache, dizziness, tiredness, lethargy, myasthenia, limb numbness, listlessness, and hypopsia.
Therefore, the disposal of blood waste is vital to health.
Disclosure of Invention
Based on the content, the invention provides the solid beverage with the function of cleaning the blood waste and the preparation method thereof, and the solid beverage can well play a role in cleaning the blood waste.
In order to achieve the purpose, the invention provides the following scheme:
according to one technical scheme of the invention, the traditional Chinese medicine composition with the function of clearing blood waste comprises the following components in parts by mass:
1-20 parts of inulin, 1-20 parts of Chinese yam, 1-20 parts of poria cocos, 1-10 parts of konjac fine powder, 1-20 parts of gynura divaricata, 1-10 parts of lotus leaves, 1-10 parts of theanine, 1-10 parts of sophora flower buds, 1-10 parts of green tea extracts and 1-10 parts of plantain seed hulls.
Further, the traditional Chinese medicine composition comprises the following components in parts by mass:
20 parts of inulin, 20 parts of Chinese yam, 20 parts of poria cocos, 5 parts of konjac fine powder, 15 parts of gynura divaricata, 5 parts of lotus leaves, 3 parts of tea theanine, 2 parts of sophora japonica, 5 parts of green tea extract and 5 parts of Plantago ovata seed husk.
According to the second technical scheme, the solid beverage with the function of clearing blood rubbish comprises the traditional Chinese medicine composition as the raw material.
In a third technical scheme of the present invention, the preparation method of the solid beverage with the blood waste cleaning effect comprises the following steps:
sequentially adding the Chinese yam, the poria cocos, the konjac powder, the gynura divaricata, the lotus leaves, the theanine, the sophora japonica, the green tea and the plantain seed hulls into the inulin, and uniformly stirring to obtain the solid beverage with the function of cleaning blood wastes.
Further, the Chinese yam, the tuckahoe, the gynura divaricata, the lotus leaves and the green tea need to be respectively subjected to water extraction and concentration treatment before being added.
Further, the water extraction and concentration treatment specifically comprises the following steps: adding 8-10 times of water, heating to boil, concentrating the extractive solution for 1.5-2 hr, drying, and pulverizing.
The technical idea of the invention is as follows:
the blood circulation system of the human body carries the transportation of nutrient substances and the discharge of metabolic wastes of the human body, the substance exchange of nutrient molecules and metabolic wastes is carried out in blood vessels at every moment in the human body, namely, the nutrient molecules enter spleen through intestinal absorption and are enriched and then sent into heart, and then are pumped to all tissues and organs of the whole body, when the nutrient molecules reach a certain tissue and organ, the substance exchange with cell groups at the place is started, the nutrient molecules are transported to cells from the blood vessels, and the cell groups discharge metabolites and metabolic wastes generated by metabolism into the blood vessels, wherein the metabolic wastes are transported to liver through blood circulation, are decomposed into small molecular substances (such as uric acid, ketone bodies, carbon dioxide, water, waste gas and the like) through the effects of oxidation, hydrolysis, enzymolysis and the like, and are finally discharged out of the body through the urinary system of kidney, the respiratory system of lung and the secretory system of sweat glands completely, the specific discharge pattern is shown in fig. 2.
According to the process of discharging the blood waste in vitro, the invention provides the solid beverage with the function of clearing the blood waste, wherein inulin has the functions of inhibiting the generation of toxic fermentation products, protecting the liver, reducing blood sugar and improving vascular disorder, and can play a role in regulating the liver; the gynura divaricata is also called gynura divaricata, has the functions of clearing lung and relieving cough, can treat bronchitis, pulmonary tuberculosis, pertussis and the like, and has the function of clearing lung; the Chinese yam is a good product for entering lung, strengthening spleen and tonifying kidney, can tonify kidney qi, has the functions of keeping blood vessel elasticity and moistening lung to arrest cough due to mucin in the Chinese yam, and has the function of tonifying kidney; the poria cocos and the lotus leaves have the effects of promoting diuresis and excreting dampness, tonifying spleen and calming heart, can well regulate the body fluid permeability level, promotes sweat gland perspiration and excretes metabolic waste, and plays a role in eliminating dampness; the green tea extract has antioxidant, anti-arteriosclerosis, antithrombotic, and anti-angiogenesis effects, and has effects of dredging collaterals; the pagodatree flower bud can reduce the permeability of capillary vessels, enhance the resistance of blood vessels and the elasticity of blood vessel walls, inhibit angiogenesis and prevent lipid peroxidation of organisms; plantago ovata husk reduces total cholesterol and Low Density Lipoprotein (LDL) levels, reducing the risk of cardiovascular disease; the konjac fine powder captures digested and absorbed fat and cholesterol and degrades blood cholesterol; bile acid can be captured and discharged outside the body, so that the content of blood waste can be reduced; theanine reduces spontaneous hypertension by regulating the amount of 5-hydroxytryptamine secreted by the central neurotransmitter in the brain, while having no effect on people with normal or low blood pressure. The components have combined action, can promote blood garbage to be discharged out of the body, and well play a role in cleaning the blood garbage.
The invention discloses the following technical effects:
the invention provides a solid beverage with the function of clearing blood waste, which can well clear the blood waste after being taken for 1-2 months before eating, can prevent the blood waste from accumulating in the blood after being taken for a long time, can prevent cardiovascular and cerebrovascular diseases, and is beneficial to body health.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings needed in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings without creative efforts.
FIG. 1 is a flow chart of the production process of the present invention;
fig. 2 is a time distribution diagram showing the discharge of blood waste from a human body through each organ.
Detailed Description
Reference will now be made in detail to various exemplary embodiments of the invention, the detailed description should not be construed as limiting the invention but as a more detailed description of certain aspects, features and embodiments of the invention.
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. Further, for numerical ranges in this disclosure, it is understood that each intervening value, between the upper and lower limit of that range, is also specifically disclosed. Every smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in a stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference herein for the purpose of disclosing and describing the methods and/or materials associated with the documents. In case of conflict with any incorporated document, the present specification will control.
It will be apparent to those skilled in the art that various modifications and variations can be made in the specific embodiments of the present disclosure without departing from the scope or spirit of the disclosure. Other embodiments will be apparent to those skilled in the art from consideration of the specification. The description and examples are intended to be illustrative only.
As used herein, the terms "comprising," "including," "having," "containing," and the like are open-ended terms that mean including, but not limited to.
The "parts" in the present invention are all parts by mass unless otherwise specified.
The production process flow of the invention is shown in figure 1.
Example 1
Accurately weighing the following raw materials:
the raw materials comprise, by mass, 20 parts of inulin, 20 parts of Chinese yam, 20 parts of poria cocos, 5 parts of konjac fine powder, 15 parts of gynura divaricata, 5 parts of lotus leaves, 3 parts of tea theanine, 2 parts of sophora flower buds, 5 parts of green tea extracts and 5 parts of Plantago ovata shells.
The preparation method comprises the following steps:
(1) the raw materials are subjected to component extraction according to the following extraction process:
chinese yam: pouring the Chinese yam into an extraction tank, adding purified water with the weight 8 times that of the Chinese yam into the extraction tank, electrically heating the water to boil, taking an extracting solution after 2 hours, adding the extracting solution into a double-effect concentrator for concentration, drying the concentrated solution in a belt dryer, and crushing the dried material to obtain the Chinese yam extract.
Tuckahoe, poria cocos: pouring Poria into an extraction tank, adding purified water 10 times of Poria weight into the extraction tank, boiling by electric heating water for 2 hr, collecting extractive solution, concentrating the extractive solution in a double-effect concentrator, drying the concentrated solution in a belt dryer, and pulverizing the dried material to obtain Poria extract.
Lotus leaf: pouring the lotus leaves into an extraction tank, adding purified water with the weight 8 times that of the lotus leaves into the extraction tank, electrically heating the water to boil, taking an extracting solution after 1.5 hours, adding the extracting solution into a double-effect concentrator for concentration, drying the concentrated solution in a belt dryer, and crushing the dried material to obtain the lotus leaf extract.
Green tea: pouring green tea into an extraction tank, adding 10 times of purified water by weight of the green tea into the extraction tank, electrically heating the water to boil, after 1.5 hours, taking an extracting solution, adding the extracting solution into a double-effect concentrator for concentration, drying the concentrated solution in a belt dryer, and crushing the dried material to obtain the green tea extract.
White seed vegetable: pouring the gynura divaricata into an extraction tank, adding purified water with the weight 8 times that of the gynura divaricata into the extraction tank, electrically heating the water to boil, concentrating the extracting solution in a double-effect concentrator after 1.5 hours, taking the extracting solution, adding the extracting solution into the double-effect concentrator for concentrating, drying the concentrated solution in a belt dryer, and crushing the dried material to obtain the gynura divaricata extract.
(2) Adding rhizoma Dioscoreae extract into inulin (labeled as mixture I) to obtain mixture II; adding Poria extract into mixture II to obtain mixture III; adding konjac fine powder into the mixture III to obtain a mixture IV; adding the gynura divaricata extract into the mixture IV to obtain a mixture V; adding the lotus leaf extract into the mixture V to obtain a mixture VI; adding theanine into the mixture VI to obtain a mixture VII; adding sophora flower bud into the mixture VII to obtain a mixture VIII; adding green tea extract to the mixture VIII to obtain a mixture IX; adding Plantago ovata forsk to mixture IX to obtain mixture X; stirring at high speed of 400r/min for 3min, mixing, and subpackaging into 4 g/bag to obtain solid beverage with blood garbage cleaning effect.
Example 2
The same as example 1, except that the raw materials consist of, by mass, 15 parts of inulin, 15 parts of yam, 18 parts of poria cocos, 8 parts of konjac fine powder, 20 parts of gynura divaricata, 7 parts of lotus leaves, 5 parts of theanine of tea leaves, 4 parts of sophora japonica, 3 parts of green tea extract and 5 parts of psyllium husk.
Example 3
The same as example 1, except that the raw materials consist of 13 parts by mass of inulin, 16 parts by mass of yam, 14 parts by mass of poria cocos, 7 parts by mass of konjac fine powder, 17 parts by mass of gynura divaricata, 6 parts by mass of lotus leaves, 4 parts by mass of theanine of tea leaves, 5 parts by mass of sophora japonica, 8 parts by mass of green tea extract and 10 parts by mass of psyllium husk.
Example 4
The same as example 1, except that the raw materials consist of, by mass, 15 parts of inulin, 17 parts of yam, 15 parts of poria cocos, 7 parts of konjac fine powder, 17 parts of gynura divaricata, 8 parts of lotus leaves, 6 parts of theanine of tea leaves, 3 parts of sophora japonica, 6 parts of green tea extract and 6 parts of psyllium husk.
Test example 1 cholesterol lowering animal test
1. Materials and instruments
1.1 Experimental animals
Mice 20 + -2 g, male and female halves, purchased from the market.
1.2 Main raw materials, drugs, reagents and instruments
The solid beverage (SFJ) with the function of cleaning blood wastes, rosuvastatin, a kit for determining serum total cholesterol by an enzyme method and an ultraviolet spectrophotometer are prepared in the embodiment 1 of the invention.
2. Method and results
2.1 preparation of animal models of hypercholesterolemia
Taking 20 +/-2 g of healthy mice, half each male mouse and half each female mouse, and establishing an experimental hypercholesterolemia mouse model by a high-fat feed feeding method. The high-fat feed is prepared as follows: 78.8% of basic feed, 10% of egg yolk powder, 10% of lard, 1% of cholesterol and 0.2% of pig bile salt.
The mice are pre-fed for 3d, 8 mice are randomly selected as a blank control group (C) during the experiment and fed with normal feed, the rest mice are fed with high fat feed for 2w to establish an experimental mouse hypercholesterolemia model, and 14d tail vein blood taking given high fat feed is performed to determine the fasting serum TC level of the molding mice.
24 mice with hyperlipidemia which are successfully modeled are randomly divided into a normal saline group (S), a rosuvastatin group (R) and a solid beverage group (SFJ) prepared in the embodiment 1 of the invention, each group comprises 8 mice, the last two groups are respectively intragastrically administered with R1.5mg/g and SFJ 180mg/kg every day, and the normal saline group is equivalent to normal saline. The administration is continued for 7 days, on day 8, the abdominal cavity of each mouse is injected with yolk emulsion 0.5ml/20g, and after 20h, the eyeball is removed and blood is taken. Separating serum, and determining the content of total cholesterol in serum of mice by using an enzyme method serum total cholesterol kit.
2.2 results and analysis
The effect of the solid drink (SFJ) prepared in example 1 of the present invention on hypercholesterolemia in mice, the results are shown in table 1.
TABLE 1
As can be seen from Table 1, SFJ has significant prophylactic and therapeutic effects on hypercholesterolemia in mice, and can reduce serum cholesterol by 32% (compared with normal saline control group).
Test example 2 triglyceride-lowering animal test
1. Materials and instruments
1.1 Experimental animals
Healthy male rats weighing 190-.
1.2 Main raw materials, drugs, reagents and instruments
The solid beverage (SFJ) with the function of cleaning blood wastes, rosuvastatin, a kit for measuring serum triglyceride by an enzyme method and an ultraviolet spectrophotometer are prepared in the embodiment 1 of the invention.
2. Method and results
2.1 preparation of animal models for hyperlipidemia
Healthy male rats are selected, and a high-fat feed feeding method is adopted to establish an experimental hyperlipidemia rat model. The high-fat feed is prepared as follows: 78.8% of basal feed, 10% of yolk powder, 10% of lard, 1% of cholesterol and 0.2% of pig bile salt.
The rats are pre-fed for 3d, 8 rats are randomly selected as a blank control group (C) during experiment and fed with normal feed, the rest rats are fed with high-fat feed, an experimental rat hypertriglyceridemia model is established, and 14d tail vein blood taking of the high-fat feed is performed to determine fasting serum TC level of the molding mice.
24 rats with high triglyceride degree successfully modeled were randomly divided into a normal saline group (S), a rosuvastatin group (R) and a solid beverage group (SFJ) prepared in the invention example 1, each group had 8 rats, the latter two groups were separately intragastrically administered with R1.5mg/g and SFJ 180mg/kg daily, and the normal saline group was given an equivalent amount of normal saline. The administration was continued for 8 days, and blood was taken by decapitation on day 9. Serum was isolated and rat serum triglyceride levels were determined enzymatically.
2.2 results and analysis
The effect of the solid drink (SFJ) prepared in example 1 of the present invention on the serum triglyceride level in rats, the results are shown in Table 2.
TABLE 2
As can be seen from Table 2, SFJ has significant preventive and clearance effects on rat hypertriglyceridemia, and can reduce the serum triglyceride content by 50% (compared with the normal saline control group).
Test example 3 animal experiments for reducing Density lipoproteins
1. Materials and instruments
1.1 Experimental animals
Healthy male rats weighing 190-.
1.2 Main raw materials, drugs, reagents and instruments
The solid beverage (SFJ) with the function of cleaning blood wastes, rosuvastatin, a kit for measuring serum low-density lipoprotein by an enzyme method and an ultraviolet spectrophotometer are prepared in the embodiment 1 of the invention.
2. Method and results
2.1 preparation of animal models for hyperlipidemia
Healthy male rats are taken, and a high-fat feed feeding method is selected to establish an experimental hyperlipidemia rat model. The high-fat feed is prepared as follows: 78.8% of basal feed, 10% of yolk powder, 10% of lard, 1% of cholesterol and 0.2% of pig bile salt.
The rats are pre-fed for 3d, 8 rats are randomly selected as a blank control group (C) during the experiment and fed with normal feed, the rest rats are fed with high-fat feed, an experimental rat high-low density lipoproteinemia model is established, and 14d tail vein blood feeding with high-fat feed is taken to determine the fasting serum TC level of the molding mice.
24 high-low density lipoprotein rats successfully modeled were randomly divided into a normal saline group (S), a rosuvastatin group (R) and a solid beverage group (SFJ) prepared in the invention example 1, 8 rats were each treated, and then the latter two groups were intragastrically administered with R1.5mg/g and SFJ 180mg/kg daily, and the normal saline group was given an equivalent amount of normal saline. The administration was continued for 8 days, and blood was taken by decapitation on day 9. Separating serum, and determining the content of serum low-density lipoprotein by enzyme method.
2.2 results and analysis
The effect of the solid beverage (SFJ) prepared in example 1 of the present invention on the serum low density lipoprotein level in rats, the results are shown in Table 3.
TABLE 3
As can be seen from Table 3, SFJ has significant preventive and eliminating effects on rat HDL, and can reduce the serum LDL content by 43% (compared with normal saline control group).
Effect verification example 1 Dong's certain quinine case
An examination report of Dongsomewhat quini before taking the solid beverage prepared in example 1 of the present invention shows:
head MRI, right basal ganglia softening range; leukoencephalopathy Fazekas grade 2; senile brain changes; the entire group of paranasal sinusitis and multiple mucosal cysts were considered.
Head MRA, intracranial arteriosclerosis; the lumen of the internal carotid lithotomy sections on two sides is limited and narrow; embryonic type basis cranial artery loop.
An examination report of Dongsomewhat quini taken two months after 3 times a day, before each meal, of the solid beverage prepared in example 1 of the present invention shows:
head MRI, softening focus of right basal ganglia area, hemosiderosis of chronic hemorrhage focus; leukoencephalopathy Fazekas grade 2; consider the full group of paranasal sinusitis.
Head MRA, intracranial arteriosclerosis; the lumen of the right internal carotid lithotomy section is limited and narrow; embryonic type basis cranial artery loop.
The examination report before and after taking the solid beverage prepared in example 1 of the present invention to some of the quinines of the board of the present invention shows: after the solid beverage prepared in the embodiment 1 of the invention is taken for two months, the 'senile cerebral change' symptom is better improved, and the 'left internal carotid lithotomy stenosis' symptom is better improved.
The self-reported condition of Dongsomewhat quini two months after taking the solid beverage prepared in example 1 of the present invention: it is evident that 3 tumors as large as date were now much smaller before the medial thigh on the right side, and that the extra-drum varicose veins on the left leg were also significantly smaller. The product (solid beverage) is taken before blood pressure is high and pressure difference is large (45/150), and the blood pressure is stable (55/128) after the product (solid beverage) is taken, and the hypotensor has been stopped. Emphysema and failure of qi are often felt before the (solid beverage) is taken, yellow and black thick phlegm can be spitted out sometimes after the (solid beverage) is taken, the body is comfortable after the phlegm is spitted out, and the face is better than the face with meat.
Effect verification example 2 case of certain suppository
An examination report of a solid beverage prepared in example 1 of the present invention before administration of a suppository shows:
low density lipoprotein elevation 3.68(<2.59), creatine kinase 172 (26-102), atherosclerosis of both lower extremities, and bilateral inter-calf-myovenous dilatation.
The examination report of two months after taking the solid drink prepared in example 1 of the present invention 3 times a day before each meal shows that:
low density lipoprotein higher by 3.70(<2.59), creatine kinase 131 (26-102), and atherosclerosis of both lower limbs.
The examination report before and after taking the solid beverage prepared in example 1 of the present invention for a certain suppository can show that: after two months after taking the solid beverage prepared in example 1 of the invention, creatine kinase is reduced from 172 to 131, the index is close to the normal value, the creatine kinase is obviously improved (creatine kinase is an important index for evaluating myocardial infarction), and the symptom of 'bilateral leg muscle intervenous dilatation' is disappeared.
Effect verification example 3 example of a certain document
Examination reports of rice text before taking the solid beverage prepared in example 1 of the present invention show that:
bilateral lower limb arteriosclerosis with plaque formation, bilateral lower limb arterial stenosis, and bilateral superficial femoral artery, considering the possibility of occlusion.
Examination of a rice article two months after taking a solid beverage prepared in example 1 of the present invention 3 times a day before each meal revealed that:
the bilateral lower limb veins were not abnormal.
Effect test example 4 Pentapheng case
Examination reports of pentoxazine before taking the solid beverage prepared in example 1 of the present invention show:
the bilateral carotid intima-media thickened and plaque formed in the posterior wall of the right carotid bulb.
Examination reports of pentopaz taken 3 times a day before each meal for two months after taking the solid beverage prepared in example 1 of the present invention show:
bilateral carotid intima-media thickening and plaque formation.
Comparison of examination reports before and after pengzheiping of solid beverages prepared in example 1 of the present invention shows that: the posterior wall of the right carotid bulb returned to normal.
Penbespine self-reported two months after taking the solid beverage prepared in example 1 of the present invention: after taking the (solid beverage) for two months, the head is clear, the face is light, and the fluctuation of the blood pressure is not much more stable than before.
Effect test example 5 case of Wangzanyan
The examination report of wangtian swallow before taking the solid beverage prepared in example 1 of the present invention shows that:
segment V4 of the left vertebral artery was mildly stenotic; blood rheology is abnormal in multiple indicators.
The examination report of a solid beverage prepared in example 1 of the present invention taken 3 times a day before meals for two months shows that:
the bilateral carotid arteries were not abnormal, and the indexes of blood rheology were all normal.
The test examples and the effect verification examples show that the solid beverage prepared by the invention has good effects of removing blood waste, reducing blood viscosity and relieving blood vessel congestion.
The above-described embodiments are merely illustrative of the preferred embodiments of the present invention, and do not limit the scope of the present invention, and various modifications and improvements of the technical solutions of the present invention can be made by those skilled in the art without departing from the spirit of the present invention, and the technical solutions of the present invention are within the scope of the present invention defined by the claims.
Claims (6)
1. A traditional Chinese medicine composition with a blood garbage cleaning effect is characterized by comprising the following components in parts by mass:
1-20 parts of inulin, 1-20 parts of Chinese yam, 1-20 parts of poria cocos, 1-10 parts of konjac fine powder, 1-20 parts of gynura divaricata, 1-10 parts of lotus leaves, 1-10 parts of theanine, 1-10 parts of sophora flower buds, 1-10 parts of green tea extracts and 1-10 parts of plantain seed hulls.
2. The traditional Chinese medicine composition with the function of clearing blood waste according to claim 1, which is characterized by comprising the following components in parts by mass:
20 parts of inulin, 20 parts of Chinese yam, 20 parts of poria cocos, 5 parts of konjac fine powder, 15 parts of gynura divaricata, 5 parts of lotus leaves, 3 parts of tea theanine, 2 parts of sophora japonica, 5 parts of green tea extract and 5 parts of Plantago ovata seed husk.
3. A solid beverage, wherein the raw material of the solid beverage comprises the Chinese medicinal composition according to claim 1 or 2.
4. A method of preparing a solid beverage according to claim 3, comprising the steps of:
sequentially adding the Chinese yam, the poria cocos, the konjac powder, the gynura divaricata, the lotus leaves, the theanine, the sophora japonica, the green tea and the plantain seed hulls into the inulin, and uniformly stirring to obtain the solid beverage with the function of cleaning blood wastes.
5. The method for preparing a solid beverage according to claim 4, wherein the yam, the tuckahoe, the gynura divaricata, the lotus leaves and the green tea are subjected to water extraction and concentration respectively before being added.
6. The method for preparing a solid beverage according to claim 5, wherein the water extraction concentration treatment is specifically: adding 8-10 times of water, heating to boil, concentrating the extractive solution for 1.5-2 hr, drying, and pulverizing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210347772.7A CN114568616A (en) | 2022-04-01 | 2022-04-01 | Solid beverage with blood garbage cleaning effect and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210347772.7A CN114568616A (en) | 2022-04-01 | 2022-04-01 | Solid beverage with blood garbage cleaning effect and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114568616A true CN114568616A (en) | 2022-06-03 |
Family
ID=81778722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210347772.7A Pending CN114568616A (en) | 2022-04-01 | 2022-04-01 | Solid beverage with blood garbage cleaning effect and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114568616A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010014749A (en) * | 1999-07-16 | 2001-02-26 | 정종문 | A drink decomposing cholesterol and a formulation decomposing the same |
| CN108404062A (en) * | 2018-06-11 | 2018-08-17 | 北京中医药大学 | Treat the Chinese medicine composition and its preparation method and application of hyperlipidemia |
| CN109157584A (en) * | 2018-10-25 | 2019-01-08 | 雷允上药业集团有限公司 | A kind of composition and its preparation method and application with auxiliary lipid-lowering function |
| CN109528884A (en) * | 2019-01-29 | 2019-03-29 | 上海中医药大学附属曙光医院 | It is a kind of regulate and control cholesterol metabolic Chinese medicine composition and its application |
-
2022
- 2022-04-01 CN CN202210347772.7A patent/CN114568616A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010014749A (en) * | 1999-07-16 | 2001-02-26 | 정종문 | A drink decomposing cholesterol and a formulation decomposing the same |
| CN108404062A (en) * | 2018-06-11 | 2018-08-17 | 北京中医药大学 | Treat the Chinese medicine composition and its preparation method and application of hyperlipidemia |
| CN109157584A (en) * | 2018-10-25 | 2019-01-08 | 雷允上药业集团有限公司 | A kind of composition and its preparation method and application with auxiliary lipid-lowering function |
| CN109528884A (en) * | 2019-01-29 | 2019-03-29 | 上海中医药大学附属曙光医院 | It is a kind of regulate and control cholesterol metabolic Chinese medicine composition and its application |
Non-Patent Citations (2)
| Title |
|---|
| 林潘海等: ""一种改善人体肥胖药膳研究"", 《2021中国药膳学术研讨会论文集》, pages 164 - 165 * |
| 高学祯等主编: "《保健食品配方原理与依据》", 中国医药科技出版社, pages: 178 - 180 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103719492B (en) | A kind of gynostemma pentaphylla protecting and nourishing liver health protection tea and preparation method thereof | |
| CN101773595B (en) | Herbal tea for clearing liver and improving eyesight | |
| CN104208302A (en) | Fructus rosae laevigatae healthy oral solution for reducing blood fat and preparation method thereof | |
| KR101627837B1 (en) | Health supplement food comprising horse bone extracts as main ingredients and sea horse and manufacturing method for the same | |
| CN103461585B (en) | Qi tonifying and health preserving herbal tea | |
| CN103749824A (en) | Gynostemma pentaphyllum health-care tea capable of lowering blood sugar and blood pressure and preparation method thereof | |
| CN106173871A (en) | A kind of fall three-hypers dumplings and preparation method thereof | |
| CN105943958A (en) | Inonotus obliquus composite solid particles for treating gout and preparing method thereof | |
| CN103749819B (en) | Fructus Corni health protection tea of a kind of hypoglycemic and preparation method thereof | |
| CN114568616A (en) | Solid beverage with blood garbage cleaning effect and preparation method thereof | |
| CN102860505A (en) | Korean medicinal healthcare food composition with effect of assisting in protecting gastric mucosa, and preparation method and use thereof | |
| CN106822684A (en) | Prevent and treat Chinese medicine composition, medicine of hyperuricemia and its preparation method and application | |
| CN105995980B (en) | A kind of composition and preparation method thereof with Weight management effect | |
| CN108142766A (en) | A kind of dendrobium candidum beverage and preparation method thereof | |
| CN1939439B (en) | Juglone and jujube capsules with memory-improving function and preparation thereof | |
| CN105998191A (en) | Application of general anesthetic to preparation of drugs for treating gout | |
| CN107648484A (en) | It is a kind of can be with the formula of anti-trioxypurine | |
| CN107854575B (en) | Red onion beverage with blood sugar reducing function and preparation method thereof | |
| CN108690775B (en) | Production method of health-preserving and health-care white spirit, health-preserving and health-care white spirit and use method thereof | |
| CN105494780A (en) | Chinese hawthorn leaf health-care tea capable of protecting liver and lowering lipid and preparation method thereof | |
| CN110477316A (en) | A kind of nutrition balanced type product formulation and preparation method thereof | |
| CN109393124A (en) | A kind of dendrobium nobile bowel tea and preparation method thereof | |
| CN109125624A (en) | One kind preventing antipodagric Chinese medical extract beverage and preparation method | |
| CN106234632A (en) | A kind of Semen Arecae dried tofu and preparation method thereof | |
| KR100804409B1 (en) | Process for making dumpling using sulfur duck |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |